Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrated Genomics in Oncogene-driven Non-small Cell Lung Cancer With Acquired Resistance to Tyrosine Kinase Inhibitors

NCT07122882 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT07122882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07122882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrated Genomics in Oncogene-driven Non-small Cell Lung Cancer With Acquired Resistance to Tyrosine Kinase Inhibitors
Lead sponsor
Chang Gung Memorial Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
September 1, 2025
Completion date
May 11, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk fusion-positive solid or cns tumors, braf v600 mutation, egfr mutation, erbb2 mutation-related tumors, kras g12c mutation, met exon 14 skipping mutation, nrg1 fusion, ntrk1 fusion positive, ntrk2 fusion positive, ntrk3 fusion positive, oncogene-addicted non small cell lung cancer, ret fusion positive, ros1 fusion positive